These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 23798862)

  • 1. CD10 and CA19.9 immunohistochemical expression in transitional cell carcinoma of the urinary bladder.
    Mohammed AS; Ali HH; Qasim BJ; Chaloob MK
    Urol Ann; 2013 Apr; 5(2):81-5. PubMed ID: 23798862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical Analysis of p53, CD10 and Ki67 Expression as Prognostic Biomarkers in Urinary Bladder Carcinomas Correlating with Age, Histomorphology, Grade and Stage: An Institutional Study of One and Half Year.
    Mohapatra AS; Mohanty P; Pradhan S; Sabat DK
    J Microsc Ultrastruct; 2023; 11(4):206-213. PubMed ID: 38213648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD10 expression in urothelial carcinoma of the bladder.
    Bahadir B; Behzatoglu K; Bektas S; Bozkurt ER; Ozdamar SO
    Diagn Pathol; 2009 Nov; 4():38. PubMed ID: 19917108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD 10 expression intensity in various grades and stages of urothelial carcinoma of urinary bladder.
    Atique M; Abbasi MS; Jamal S; Khadim MT; Akhtar F; Jamal N
    J Coll Physicians Surg Pak; 2014 May; 24(5):351-5. PubMed ID: 24848395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD10 and E-cad expression in urinary bladder urothelial and squamous cell carcinoma.
    Omran OM
    J Environ Pathol Toxicol Oncol; 2012; 31(3):203-12. PubMed ID: 23339695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of CD10 in urothelial carcinoma of the bladder and its correlation with histopathological grade, pathological stage, and survival of patients.
    Shukla SK; Chandra S; Chauhan N; Sarpal R
    J Cancer Res Ther; 2021; 17(4):887-892. PubMed ID: 34528537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Determination of urinary CA19-9 levels in urothelial cancer--assessment of its role in diagnosis].
    Noto K; Fujime M; Isobe H; Wakumato Y; Kawachi Y
    Nihon Hinyokika Gakkai Zasshi; 1997 Mar; 88(3):406-13. PubMed ID: 9125864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of CA19-9 as a tumor marker in urothelial malignancy.
    Chuang CK; Liao SK
    Scand J Urol Nephrol; 2004; 38(5):359-65. PubMed ID: 15764245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD10 expression in urothelial bladder carcinomas: a pilot study.
    Bircan S; Candir O; Kapucuoglu N; Serel TA; Ciris M; Karahan N
    Urol Int; 2006; 77(2):107-13. PubMed ID: 16888412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD10 expression in urinary bladder urothelial carcinoma is associated with high-tumor grade and stage.
    Al-Maghrabi J
    Pak J Med Sci; 2023; 39(1):192-197. PubMed ID: 36694735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing CD 10 Expression Level and Its Prognostic Impact in Egyptian Patients with Urothelial Carcinoma.
    Hussien MT; Helmy E; Elsaba TM; Elkady A; Alrefai H; Hetta HF
    Asian Pac J Cancer Prev; 2020 Jun; 21(6):1573-1583. PubMed ID: 32592351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transitional cell neoplasms of the ovary and urinary bladder: a comparative immunohistochemical analysis.
    Soslow RA; Rouse RV; Hendrickson MR; Silva EG; Longacre TA
    Int J Gynecol Pathol; 1996 Jul; 15(3):257-65. PubMed ID: 8811388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urinary level of CA19-9 as a tumor marker in urothelial carcinoma of the bladder.
    Pal K; Roy S; Mondal SA; Chatterjee U; Tiwari P; Bera M
    Urol J; 2011; 8(3):203-8. PubMed ID: 21910099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significance of CA19-9 in predicting the prognosis of urothelial carcinoma: a hospital based study from Nepal.
    Jha DK; Mittal A; Gupta SP; Sathian B
    Asian Pac J Cancer Prev; 2013; 14(7):4067-9. PubMed ID: 23991954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clear cell carcinoma of the urinary bladder: a report and comparison of four tumors of mullerian origin and nine of probable urothelial origin with discussion of histogenesis and diagnostic problems.
    Oliva E; Amin MB; Jimenez R; Young RH
    Am J Surg Pathol; 2002 Feb; 26(2):190-7. PubMed ID: 11812940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical usefulness of CEA, CA19-9, and CYFRA 21-1 as tumor markers for urothelial bladder carcinoma.
    Washino S; Hirai M; Matsuzaki A; Kobayashi Y
    Urol Int; 2011; 87(4):420-8. PubMed ID: 22041857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of P27 (Kip 1) and MUC1 in papillary transitional cell carcinoma of the urinary bladder.
    Abd Elazeez TA; El-Balshy Ael-L; Khalil MM; El-Tabye MM; Abdul-Halim H
    Urol Ann; 2011 Jan; 3(1):8-13. PubMed ID: 21346826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inverted papilloma of the bladder: a review and an analysis of the recent literature of 365 patients.
    Picozzi S; Casellato S; Bozzini G; Ratti D; Macchi A; Rubino B; Pace G; Carmignani L
    Urol Oncol; 2013 Nov; 31(8):1584-90. PubMed ID: 22520573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphorylated H2AX in noninvasive low grade urothelial carcinoma of the bladder: correlation with tumor recurrence.
    Cheung WL; Albadine R; Chan T; Sharma R; Netto GJ
    J Urol; 2009 Mar; 181(3):1387-92. PubMed ID: 19157440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of survivin in squamous cell carcinoma and transitional cell carcinoma of the urinary bladder: a comparative immunohistochemical study.
    Makboul R; Refaiy AE; Badary FA; Abdelkawi IF; Merseburger AS; Mohammed RA
    Korean J Urol; 2015 Jan; 56(1):31-40. PubMed ID: 25598934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.